Delivery Order 36C26323D0087-36C26326N0392
- Not listed
- The Department of Veterans Affairs, Veterans Integrated Service Network 23 (VISN 23), awarded a delivery order to Veracyte, Inc. for reference laboratory services under an Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The award, issued on May 1, 2024, carries a ceiling value of $11.2K and an ultimate completion date of April 30, 2025. Veracyte, Inc., a South San Francisco-based medical diagnostic company specializing in advanced genomic testing, will deliver molecular and genomic...
- The Department of Veterans Affairs, Veterans Integrated Service Network 23 (VISN 23), awarded a delivery order valued at $168,000 to Veracyte, Inc. for reference laboratory services with a completion date of April 30, 2026. This task order was issued under an existing Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Veracyte Reference Laboratory Services with VISN 23, which carries a total ceiling value of $2 million through April 2028. The contract utilizes firm fixed pricing and was...
- The Department of Veterans Affairs, Veterans Integrated Service Network (VISN) 23, awarded a $112,200 firm fixed-price delivery order to Veracyte, Inc., a South San Francisco-based medical diagnostic company specializing in advanced genomic testing services. The task order, effective May 1, 2026, with an ultimate completion date of April 30, 2027, will be performed at Veracyte's headquarters location in South San Francisco, California. This delivery order was issued without a small business...
- The Department of Veterans Affairs, Veterans Integrated Service Network 8 (VISN 8), awarded a delivery order valued at $96,960 to Veracyte, Inc. for gene testing services. The award, issued on February 5, 2026, is a firm fixed-price delivery order with an ultimate completion date of February 4, 2027, and carries no small business set-aside designation. The contract will be performed in South San Francisco, California, where Veracyte maintains its headquarters. This delivery order is issued under...
- The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 23, awarded a $168,000 firm fixed-price delivery order to Veracyte, Inc. on May 1, 2026, to support genomic testing services at the Minneapolis VA facility through April 30, 2027. This task order was issued under Veracyte's existing $2 million indefinite delivery/indefinite quantity contract with VISN 23 for reference laboratory services, which runs through April 30, 2028. The award carries no small business set-aside...
- Veracyte, Inc. was awarded a $451.2K firm fixed-price purchase order by Veterans Integrated Service Network 17 (VISN 17), a civilian component of the Department of Veterans Affairs, for genomic laboratory testing services. The contract was awarded on August 15, 2022, with an ultimate completion date of August 14, 2027, and will be performed in Dallas, Texas. This award carries no small business set-aside designation and represents a continuation of Veracyte's established relationship with the...
- The Department of Veterans Affairs, Veterans Integrated Service Network (VISN) 23, awarded a delivery order valued at $85,000 to Veracyte, Inc. for Afirma thyroid testing services supporting the Fargo VA Health Care System. This firm fixed-price delivery order, issued on May 1, 2026, is scheduled for completion by April 30, 2027. The award carries no small business set-aside designation and reflects the proprietary and specialized nature of Veracyte's genomic diagnostic capabilities. The work...
- This federal contract award is a Firm Fixed Price Delivery Order under the VERACYTE REFERENCE LABORATORY SERVICES Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Veterans Integrated Service Network (VISN) 23. The contract, with a ceiling value of $53,400.00, is for reference laboratory services to be provided by the prime contractor, Veracyte, Inc., a for-profit medical diagnostics company. The contract has an ultimate completion date of April 30, 2025 and was awarded on October 1,...
- This is a federal contract award by the Department of Veterans Affairs' Veterans Integrated Service Network (VISN) 23 to Veracyte, Inc., a medical diagnostic company specializing in advanced genomic testing services. The contract is an Indefinite Delivery/Indefinite Quantity (IDIQ) with a ceiling value of $72,800.00 for providing reference laboratory services. The contract is a firm fixed-price delivery order with an ultimate completion date of April 30, 2025. Veracyte will perform these testing...
- This is a federal contract award to Veracyte, Inc., a for-profit medical diagnostic company, by the Veterans Integrated Service Network 23 (VISN 23), a division of the Department of Veterans Affairs (VA). The contract is an Indefinite Delivery, Indefinite Quantity (IDIQ) with a ceiling value of $112,200.00 for reference laboratory services. The contract is a firm fixed-price delivery order with an ultimate completion date of April 30, 2026. The contract is not set aside and was awarded on May 1,...
- 36C26323D0087Indefinite Delivery Contract
- 36C26323D0087-36C26326N0392Delivery Order
The Department of Veterans Affairs, Veterans Integrated Service Network 23 (VISN 23), awarded a $67.6K delivery order to Veracyte, Inc. on May 1, 2026, for reference laboratory and genomic testing services supporting the NWI-Omaha VA facility. The order is structured as a firm fixed-price delivery order with a completion deadline of September 30, 2026, and carries no small business set-aside designation. This award is issued under Veracyte's existing $2M indefinite delivery/indefinite quantity (IDIQ) contract with VISN 23 for reference laboratory services, which runs through April 30, 2028, and has previously supported thyroid biopsy testing, reference laboratory services, and specialty genomic testing across VA facilities in northern and central California. Veracyte, Inc., headquartered in South San Francisco, California, is a specialized medical diagnostic company providing proprietary molecular genomic testing services for precision medicine applications across federal healthcare systems. The company maintains an extensive federal contract portfolio serving the VA, Defense Health Agency, and Indian Health Service through multiple IDIQs and blanket purchase agreements under the GSA Medical Laboratory Testing and Analysis Services Federal Supply Schedule. Veracyte's core offerings include the Decipher Prostate Cancer Test for prostate cancer risk assessment and the Afirma Genomic Sequencing Classifier for thyroid nodule malignancy risk stratification, with recent contract awards ranging from approximately $12.9K to $1.85M across multiple VISN networks and other federal healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $67.6k | 2/24/26 |